Experimental Hematology & Oncology

Article	Citations
Complex roles of cAMP–PKA–CREB signaling in cancer	196
CD44 as a tumor biomarker and therapeutic target	170
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017	120
Risk factors and outcome of COVID-19 in patients with hematological malignancies	109
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients	65
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC	63
Engineering better chimeric antigen receptor T cells	61
Research progress on dendritic cell vaccines in cancer immunotherapy	59
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017	57
Macrophage, the potential key mediator in CAR-T related CRS	53
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition	51
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	50
Role of m6A writers, erasers and readers in cancer	48
MiRNA-mediated EMT and CSCs in cancer chemoresistance	46
Clinical implications of recurrent gene mutations in acute myeloid leukemia	45
Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma	44
Recent advances and challenges of bispecific antibodies in solid tumors	42
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes	41
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder	40
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL	38
Heterogeneity of the tumor immune microenvironment and its clinical relevance	38
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients	35
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	35
COVID-19 vaccination associated severe immune thrombocytopenia	35
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma	34

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia	33
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	33
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy	31
Breast cancer heterogeneity and its implication in personalized precision therapy	31
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma	30
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma	28
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4	28
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors	28
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	27
Recent advances in Lynch syndrome	26
m6A binding protein YTHDF2 in cancer	24
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas	24
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	24
The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017	24
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment	23
TCR engineered T cells for solid tumor immunotherapy	23
Current insight into the regulation of PD-L1 in cancer	22
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma	21
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	21
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 si	21
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	21
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China	21
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study	20
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome	20
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia	20
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma	19
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	19
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	19
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer	18
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	18
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis	17
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside	17
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance	16
Increasing cure rates of solid tumors by immune checkpoint inhibitors	16
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	16
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	16
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review	16
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion	15
Function and clinical significance of N6-methyladenosine in digestive system tumours	15
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis	15
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases	15
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio	15
The metabolic adaptation mechanism of metastatic organotropism	15
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation	14
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	14
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	14
Recent updates for antibody therapy for acute lymphoblastic leukemia	14
p53 amyloid aggregation in cancer: function, mechanism, and therapy	14
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers	14
Frontiers in the COVID-19 vaccines development	13

Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis	13
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma	13
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment	13
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	13
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma	13
Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models	13
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	13
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort	13
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma	12
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information	12
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel	12
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway	12
Targeting phosphoglycerate dehydrogenase in multiple myeloma	12
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	12
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	12
Targeting metabolic reprogramming in chronic lymphocytic leukemia	12
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy	12
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	12
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	12
RDGN-based predictive model for the prognosis of breast cancer	11
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells	11
RHO GTPase family in hepatocellular carcinoma	11
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU	11
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	11
Development of human prostate cancer stem cells involves epigenomic alteration and PI3K/AKT pathway activation	11
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis	11
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP	11
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial	10
Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis	10
Platelet desialylation and TFH cells–the novel pathway of immune thrombocytopenia	10
Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns	10
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma	10
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	10
Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia	10
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR	10
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	10
Increased TOX expression associates with exhausted T cells in patients with multiple myeloma	10
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing	9
The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition	9
Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells	9
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country	9
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with defe	9
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis	9
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma	8
miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR	8
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	8
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML	8
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting	8
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	8
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified	8
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	8
New insight into circRNAs: characterization, strategies, and biomedical applications	7
Emerging roles of m6A RNA modification in cancer therapeutic resistance	7
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients	7
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	7
The importance of N6-methyladenosine modification in tumor immunity and immunotherapy	7
JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression	7
Chimeric antigen receptor engineered natural killer cells for cancer therapy	7
Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine	6
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide	6
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells	6
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	6
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications	6
Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center	6
Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer	6
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis	6
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	6
G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway	6
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	6
Progress in molecular feature of smoldering mantle cell lymphoma	6
Low expression of PEBP1P2 promotes metastasis of clear cell renal cell carcinoma by post-transcriptional regulation of PEBP1 and KLF13 mRNA	6
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect	6
Trends in platelet count among cancer patients	6
Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model	6
Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits	5
Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia	5
Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma	5
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification	5
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells	5
ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer	5

Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	5
Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study	5
Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis	5
Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial	5
Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway	5
Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial	5
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	5
Focal adhesion kinase: from biological functions to therapeutic strategies	5
Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era	5
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells	5
The role of organoids in cancer research	5
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway	5
Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	5
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation	5
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target	5